Proximal Tibia Tumour Location and Curettage Are Major Risk Factors of Local Recurrence in Giant Cell Tumour of Bone
Giant cell tumour of bone (GCTB) is one of the most common local aggressive tumourous lesions with a wide variety of biological behaviour. However, there are no clear indicative criteria when choosing the type of procedure and the complication rates remain high, especially in terms of local recurren...
Gespeichert in:
Veröffentlicht in: | Cancers 2023-09, Vol.15 (18), p.4664 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 18 |
container_start_page | 4664 |
container_title | Cancers |
container_volume | 15 |
creator | Mahdal, Michal Tomáš, Tomáš Apostolopoulos, Vasileios Adámková, Dagmar Múdry, Peter Staniczková Zambo, Iva Pazourek, Lukáš |
description | Giant cell tumour of bone (GCTB) is one of the most common local aggressive tumourous lesions with a wide variety of biological behaviour. However, there are no clear indicative criteria when choosing the type of procedure and the complication rates remain high, especially in terms of local recurrence. The purpose of the study was to (1) identify the main risk factors for local recurrence, (2) evaluate the recurrence-free survival in dependence on neoadjuvant denosumab use and the type of procedure, and (3) compare the functional outcomes after curettage and en bloc resection. The group included 102 patients with GCTB treated between 2006 and 2020. The mean age of patients was 34.4 years (15–79). The follow-up period was 8.32 years (2–16) on average. Local recurrence occurred in 14 patients (29.8%) who underwent curettage and in 5 patients (10.6%) after en bloc resection. Curettage was shown to be a factor in increasing recurrence rates (OR = 3.64 [95% CI: 1.19–11.15]; p = 0.023). Tibial location was an independent risk factor for local recurrence regardless of the type of surgery (OR = 3.22 [95% CI: 1.09–9.48]; p = 0.026). The recurrence-free survival rate of patients treated with resection and denosumab was higher compared to other treatments at five years postoperatively (p = 0.0307). Functional ability and pain as reported by patients at the latest follow-up were superior after curettage compared to resection for upper and lower extremity (mean difference: −4.00 [95% CI: –6.81 to −1.18]; p < 0.001 and mean difference: −5.36 [95% CI: −3.74 to −6.97]; p < 0.001, respectively). Proximal tibia tumour location and curettage were shown to be major risk factors for local recurrence in GCTB regardless of neoadjuvant denosumab treatment. The recurrence-free survival rate of patients treated with resection and denosumab was higher compared to other treatments. The functional outcome of patients after curettage was better compared to en bloc resection. |
doi_str_mv | 10.3390/cancers15184664 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10526787</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A766928037</galeid><sourcerecordid>A766928037</sourcerecordid><originalsourceid>FETCH-LOGICAL-c466t-f5eeefebb60e8343d639ff1268629424af7599acddb0c7be1f3529f616a502e53</originalsourceid><addsrcrecordid>eNptks9vFCEUxyeNJm1qz15JvPSyLT8GGE7NdmOryRpNs54Jwzy2rDPQAmP0v5e11dpGOPAC3_d9fOA1zVuCzxhT-NyaYCFlwknXCtEeNEcUS7oQQrWv_okPm5Ocd7gOxogU8qgpX1L84Sczoo3vvUGbeYpzQutoTfExIBMGtJoTlGK2gJYJ0Ceziwnd-PwNXRlbYsoout8JI7oBO6cE9S7IB3TtTShoBeP4x7YKL2OAN81rZ8YMJ4_rcfP16v1m9WGx_nz9cbVcL2yFKAvHAcBB3wsMHWvZIJhyjlDRCapa2honuVLGDkOPreyBOMapcoIIwzEFzo6biwffu7mfYLAQSjKjvksVOP3U0Xj9_CT4W72N3zXBnArZyepw-uiQ4v0MuejJZ1uJTIA4Z007iUmruMBV-u6FdFeRQ-WrKqGo4qTlT6qtGUH74GItbPemeinrF9EOs33Zs_-o6hxg8ra-oPN1_1nC-UOCTTHnBO4vJMF63yH6RYewX-aor1M</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2869295145</pqid></control><display><type>article</type><title>Proximal Tibia Tumour Location and Curettage Are Major Risk Factors of Local Recurrence in Giant Cell Tumour of Bone</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><creator>Mahdal, Michal ; Tomáš, Tomáš ; Apostolopoulos, Vasileios ; Adámková, Dagmar ; Múdry, Peter ; Staniczková Zambo, Iva ; Pazourek, Lukáš</creator><creatorcontrib>Mahdal, Michal ; Tomáš, Tomáš ; Apostolopoulos, Vasileios ; Adámková, Dagmar ; Múdry, Peter ; Staniczková Zambo, Iva ; Pazourek, Lukáš</creatorcontrib><description>Giant cell tumour of bone (GCTB) is one of the most common local aggressive tumourous lesions with a wide variety of biological behaviour. However, there are no clear indicative criteria when choosing the type of procedure and the complication rates remain high, especially in terms of local recurrence. The purpose of the study was to (1) identify the main risk factors for local recurrence, (2) evaluate the recurrence-free survival in dependence on neoadjuvant denosumab use and the type of procedure, and (3) compare the functional outcomes after curettage and en bloc resection. The group included 102 patients with GCTB treated between 2006 and 2020. The mean age of patients was 34.4 years (15–79). The follow-up period was 8.32 years (2–16) on average. Local recurrence occurred in 14 patients (29.8%) who underwent curettage and in 5 patients (10.6%) after en bloc resection. Curettage was shown to be a factor in increasing recurrence rates (OR = 3.64 [95% CI: 1.19–11.15]; p = 0.023). Tibial location was an independent risk factor for local recurrence regardless of the type of surgery (OR = 3.22 [95% CI: 1.09–9.48]; p = 0.026). The recurrence-free survival rate of patients treated with resection and denosumab was higher compared to other treatments at five years postoperatively (p = 0.0307). Functional ability and pain as reported by patients at the latest follow-up were superior after curettage compared to resection for upper and lower extremity (mean difference: −4.00 [95% CI: –6.81 to −1.18]; p < 0.001 and mean difference: −5.36 [95% CI: −3.74 to −6.97]; p < 0.001, respectively). Proximal tibia tumour location and curettage were shown to be major risk factors for local recurrence in GCTB regardless of neoadjuvant denosumab treatment. The recurrence-free survival rate of patients treated with resection and denosumab was higher compared to other treatments. The functional outcome of patients after curettage was better compared to en bloc resection.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers15184664</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Curettage ; Denosumab ; Diseases ; Fractures ; Gender ; Patients ; Relapse ; Risk factors ; Statistical analysis ; Surgery ; Tibia ; Tumors</subject><ispartof>Cancers, 2023-09, Vol.15 (18), p.4664</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c466t-f5eeefebb60e8343d639ff1268629424af7599acddb0c7be1f3529f616a502e53</citedby><cites>FETCH-LOGICAL-c466t-f5eeefebb60e8343d639ff1268629424af7599acddb0c7be1f3529f616a502e53</cites><orcidid>0000-0002-2136-9136 ; 0000-0001-9719-4769 ; 0000-0003-3434-7937 ; 0000-0003-1535-1842 ; 0000-0002-1189-0702</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526787/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10526787/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids></links><search><creatorcontrib>Mahdal, Michal</creatorcontrib><creatorcontrib>Tomáš, Tomáš</creatorcontrib><creatorcontrib>Apostolopoulos, Vasileios</creatorcontrib><creatorcontrib>Adámková, Dagmar</creatorcontrib><creatorcontrib>Múdry, Peter</creatorcontrib><creatorcontrib>Staniczková Zambo, Iva</creatorcontrib><creatorcontrib>Pazourek, Lukáš</creatorcontrib><title>Proximal Tibia Tumour Location and Curettage Are Major Risk Factors of Local Recurrence in Giant Cell Tumour of Bone</title><title>Cancers</title><description>Giant cell tumour of bone (GCTB) is one of the most common local aggressive tumourous lesions with a wide variety of biological behaviour. However, there are no clear indicative criteria when choosing the type of procedure and the complication rates remain high, especially in terms of local recurrence. The purpose of the study was to (1) identify the main risk factors for local recurrence, (2) evaluate the recurrence-free survival in dependence on neoadjuvant denosumab use and the type of procedure, and (3) compare the functional outcomes after curettage and en bloc resection. The group included 102 patients with GCTB treated between 2006 and 2020. The mean age of patients was 34.4 years (15–79). The follow-up period was 8.32 years (2–16) on average. Local recurrence occurred in 14 patients (29.8%) who underwent curettage and in 5 patients (10.6%) after en bloc resection. Curettage was shown to be a factor in increasing recurrence rates (OR = 3.64 [95% CI: 1.19–11.15]; p = 0.023). Tibial location was an independent risk factor for local recurrence regardless of the type of surgery (OR = 3.22 [95% CI: 1.09–9.48]; p = 0.026). The recurrence-free survival rate of patients treated with resection and denosumab was higher compared to other treatments at five years postoperatively (p = 0.0307). Functional ability and pain as reported by patients at the latest follow-up were superior after curettage compared to resection for upper and lower extremity (mean difference: −4.00 [95% CI: –6.81 to −1.18]; p < 0.001 and mean difference: −5.36 [95% CI: −3.74 to −6.97]; p < 0.001, respectively). Proximal tibia tumour location and curettage were shown to be major risk factors for local recurrence in GCTB regardless of neoadjuvant denosumab treatment. The recurrence-free survival rate of patients treated with resection and denosumab was higher compared to other treatments. The functional outcome of patients after curettage was better compared to en bloc resection.</description><subject>Curettage</subject><subject>Denosumab</subject><subject>Diseases</subject><subject>Fractures</subject><subject>Gender</subject><subject>Patients</subject><subject>Relapse</subject><subject>Risk factors</subject><subject>Statistical analysis</subject><subject>Surgery</subject><subject>Tibia</subject><subject>Tumors</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptks9vFCEUxyeNJm1qz15JvPSyLT8GGE7NdmOryRpNs54Jwzy2rDPQAmP0v5e11dpGOPAC3_d9fOA1zVuCzxhT-NyaYCFlwknXCtEeNEcUS7oQQrWv_okPm5Ocd7gOxogU8qgpX1L84Sczoo3vvUGbeYpzQutoTfExIBMGtJoTlGK2gJYJ0Ceziwnd-PwNXRlbYsoout8JI7oBO6cE9S7IB3TtTShoBeP4x7YKL2OAN81rZ8YMJ4_rcfP16v1m9WGx_nz9cbVcL2yFKAvHAcBB3wsMHWvZIJhyjlDRCapa2honuVLGDkOPreyBOMapcoIIwzEFzo6biwffu7mfYLAQSjKjvksVOP3U0Xj9_CT4W72N3zXBnArZyepw-uiQ4v0MuejJZ1uJTIA4Z007iUmruMBV-u6FdFeRQ-WrKqGo4qTlT6qtGUH74GItbPemeinrF9EOs33Zs_-o6hxg8ra-oPN1_1nC-UOCTTHnBO4vJMF63yH6RYewX-aor1M</recordid><startdate>20230901</startdate><enddate>20230901</enddate><creator>Mahdal, Michal</creator><creator>Tomáš, Tomáš</creator><creator>Apostolopoulos, Vasileios</creator><creator>Adámková, Dagmar</creator><creator>Múdry, Peter</creator><creator>Staniczková Zambo, Iva</creator><creator>Pazourek, Lukáš</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2136-9136</orcidid><orcidid>https://orcid.org/0000-0001-9719-4769</orcidid><orcidid>https://orcid.org/0000-0003-3434-7937</orcidid><orcidid>https://orcid.org/0000-0003-1535-1842</orcidid><orcidid>https://orcid.org/0000-0002-1189-0702</orcidid></search><sort><creationdate>20230901</creationdate><title>Proximal Tibia Tumour Location and Curettage Are Major Risk Factors of Local Recurrence in Giant Cell Tumour of Bone</title><author>Mahdal, Michal ; Tomáš, Tomáš ; Apostolopoulos, Vasileios ; Adámková, Dagmar ; Múdry, Peter ; Staniczková Zambo, Iva ; Pazourek, Lukáš</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c466t-f5eeefebb60e8343d639ff1268629424af7599acddb0c7be1f3529f616a502e53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Curettage</topic><topic>Denosumab</topic><topic>Diseases</topic><topic>Fractures</topic><topic>Gender</topic><topic>Patients</topic><topic>Relapse</topic><topic>Risk factors</topic><topic>Statistical analysis</topic><topic>Surgery</topic><topic>Tibia</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mahdal, Michal</creatorcontrib><creatorcontrib>Tomáš, Tomáš</creatorcontrib><creatorcontrib>Apostolopoulos, Vasileios</creatorcontrib><creatorcontrib>Adámková, Dagmar</creatorcontrib><creatorcontrib>Múdry, Peter</creatorcontrib><creatorcontrib>Staniczková Zambo, Iva</creatorcontrib><creatorcontrib>Pazourek, Lukáš</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mahdal, Michal</au><au>Tomáš, Tomáš</au><au>Apostolopoulos, Vasileios</au><au>Adámková, Dagmar</au><au>Múdry, Peter</au><au>Staniczková Zambo, Iva</au><au>Pazourek, Lukáš</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Proximal Tibia Tumour Location and Curettage Are Major Risk Factors of Local Recurrence in Giant Cell Tumour of Bone</atitle><jtitle>Cancers</jtitle><date>2023-09-01</date><risdate>2023</risdate><volume>15</volume><issue>18</issue><spage>4664</spage><pages>4664-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Giant cell tumour of bone (GCTB) is one of the most common local aggressive tumourous lesions with a wide variety of biological behaviour. However, there are no clear indicative criteria when choosing the type of procedure and the complication rates remain high, especially in terms of local recurrence. The purpose of the study was to (1) identify the main risk factors for local recurrence, (2) evaluate the recurrence-free survival in dependence on neoadjuvant denosumab use and the type of procedure, and (3) compare the functional outcomes after curettage and en bloc resection. The group included 102 patients with GCTB treated between 2006 and 2020. The mean age of patients was 34.4 years (15–79). The follow-up period was 8.32 years (2–16) on average. Local recurrence occurred in 14 patients (29.8%) who underwent curettage and in 5 patients (10.6%) after en bloc resection. Curettage was shown to be a factor in increasing recurrence rates (OR = 3.64 [95% CI: 1.19–11.15]; p = 0.023). Tibial location was an independent risk factor for local recurrence regardless of the type of surgery (OR = 3.22 [95% CI: 1.09–9.48]; p = 0.026). The recurrence-free survival rate of patients treated with resection and denosumab was higher compared to other treatments at five years postoperatively (p = 0.0307). Functional ability and pain as reported by patients at the latest follow-up were superior after curettage compared to resection for upper and lower extremity (mean difference: −4.00 [95% CI: –6.81 to −1.18]; p < 0.001 and mean difference: −5.36 [95% CI: −3.74 to −6.97]; p < 0.001, respectively). Proximal tibia tumour location and curettage were shown to be major risk factors for local recurrence in GCTB regardless of neoadjuvant denosumab treatment. The recurrence-free survival rate of patients treated with resection and denosumab was higher compared to other treatments. The functional outcome of patients after curettage was better compared to en bloc resection.</abstract><cop>Basel</cop><pub>MDPI AG</pub><doi>10.3390/cancers15184664</doi><orcidid>https://orcid.org/0000-0002-2136-9136</orcidid><orcidid>https://orcid.org/0000-0001-9719-4769</orcidid><orcidid>https://orcid.org/0000-0003-3434-7937</orcidid><orcidid>https://orcid.org/0000-0003-1535-1842</orcidid><orcidid>https://orcid.org/0000-0002-1189-0702</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2072-6694 |
ispartof | Cancers, 2023-09, Vol.15 (18), p.4664 |
issn | 2072-6694 2072-6694 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10526787 |
source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central |
subjects | Curettage Denosumab Diseases Fractures Gender Patients Relapse Risk factors Statistical analysis Surgery Tibia Tumors |
title | Proximal Tibia Tumour Location and Curettage Are Major Risk Factors of Local Recurrence in Giant Cell Tumour of Bone |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T18%3A44%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Proximal%20Tibia%20Tumour%20Location%20and%20Curettage%20Are%20Major%20Risk%20Factors%20of%20Local%20Recurrence%20in%20Giant%20Cell%20Tumour%20of%20Bone&rft.jtitle=Cancers&rft.au=Mahdal,%20Michal&rft.date=2023-09-01&rft.volume=15&rft.issue=18&rft.spage=4664&rft.pages=4664-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers15184664&rft_dat=%3Cgale_pubme%3EA766928037%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2869295145&rft_id=info:pmid/&rft_galeid=A766928037&rfr_iscdi=true |